Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
TipRanks (Wed, 27-Mar 4:05 PM ET)
TipRanks (Wed, 27-Mar 8:20 AM ET)
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024
TipRanks (Tue, 26-Mar 11:15 AM ET)
Aprea Therapeutics GAAP EPS of -$0.92
Seeking Alpha News (Tue, 26-Mar 8:05 AM ET)
Globe Newswire (Tue, 26-Mar 7:45 AM ET)
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Globe Newswire (Mon, 11-Mar 8:30 AM ET)
Globe Newswire (Mon, 11-Mar 8:29 AM ET)
Globe Newswire (Tue, 5-Mar 4:45 PM ET)
Globe Newswire (Tue, 6-Feb 8:01 AM ET)
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Globe Newswire (Tue, 30-Jan 8:00 AM ET)
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.
As of March 27, 2024, APRE stock price climbed to $6.07 with 16,557 million shares trading.
APRE has a beta of 1.50, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.07 to the broad based SPY ETF.
APRE has a market cap of $22.68 million. This is considered a Sub-Micro Cap stock.
Last quarter Aprea Therapeutics reported $14,075 in Revenue and -$.92 earnings per share. This fell short of revenue expectation by $-95,925 and missed earnings estimates by -$.15.
In the last 3 years, APRE stock traded as high as $156.00 and as low as $.47.
The top ETF exchange traded funds that APRE belongs to (by Net Assets): VTI, VXF, DFAC.
APRE stock has underperformed the market in the last year with a return of +29.1%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in APRE shares. However, APRE has outperformed the market in the last 3 month and 2 week periods, returning +64.1% and +9.4%, while SPY returned +10.1% and +1.7%, respectively. This indicates APRE has been having a stronger performance recently.
APRE support price is $5.41 and resistance is $6.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE stock will trade within this expected range on the day.